REGENXBIO to Present Phase II Trial Results for Experimental AMD Gene Therapy
REGENXBIO Inc. (NASDAQ:RGNX) has recently revealed that they will be sharing the details of their Phase II trial results for their investigational gene therapy, ABBV-RGX-314, aimed at treating wet age-related macular degeneration (AMD). The company is set to present these findings at the Hawaiian Eye and Retina 2024 Meeting, which is scheduled to take place from January 13-19 in Maui, HI.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
